Drugs / piperacillin/tazobactam
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01370616 Comparator | Sep 2011 → Dec 2013 | skin infection | Merck Sharp & Dohme LLC | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | piperacillin/tazobactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01370616 ↗ |
| Known as | Piperacillin/tazobactam sodium | “Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days” NCT01370616 ↗ |
| Route | Intravenous | “4.5 g, IV every 8 hours” NCT01370616 ↗ |